Novel Covid-19 Vaccine
COVID-19
Pre-clinicalActive
Key Facts
About Oxford Expression Technologies
Oxford Expression Technologies (OET) is a private biotechnology company founded in 2001 (incorporated 2007) as a spin-out from Oxford Brookes University and the Natural Environment Research Council. The company has established itself as a leading global provider of baculovirus expression products and services, centered on its proprietary flash BAC™ platform for high-throughput recombinant protein and virus-like particle production. OET leverages its expertise in insect, mammalian, and bacterial expression systems to serve clients in drug discovery, vaccine development, and diagnostics, while also pursuing its own internal vaccine development programs through grant-funded collaborations.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |
| UOL COVID-19 Test | Uh-Oh Labs | Approved |
| Lagevrio (molnupiravir) | Ridgeback Biotherapeutics | Approved/EUA |
| CVXGA | CyanVac | Phase 2 |